EPO

(redirected from Epoetin)
Also found in: Thesaurus, Medical, Encyclopedia.

EPO

abbreviation for
(Pharmacology) erythropoietin
Translations
References in periodicals archive ?
Epoetin zeta (epoetin theta) - 20,000 iu / 1 ml solution for injection in pre-filled syringe 1 pre-filled syringe with safety needle with 1 ml.
In that, the FDA had come to a conclusion that the proposed biosimilar epoetin alfa has a lot of similarities to its reference candidates Epogen and Procrit (epoetin alfa).
Notably, the average epoetin dose increased more than 4-fold between 1991 and 2005 in dialysis patients (Steinbrook 2006), reaching nearly $2 billion in 2005 (GAO 2006; United States Renal Data System [USRDS] 2006).
Approval was based on two randomized open-label studies of 1,608 patients with CKD who were on dialysis, who, after their hemoglobin levels were stabilized with epoetin, were randomized to continue treatment with epoetin or peginesatide.
Can the administration of intravenous ascorbic acid improve the response to epoetin alfa in patients on hemodialysis?
Erythropoietic-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa are frequently used for the treatment of anemia of chronic kidney disease (CKD) (KDOQI, 2006; Moist, 2008).
Clinical trials have shown that sc administration of epoetin beta is less painful than sc administration of either epoetin alfa or darbepoetin alfa (Frenken et al.
A greater mortality rate in patients treated with epoetin alfa in a German study evaluating the drug's potential neuroprotective effects in stroke patients is the subject of an ongoing Food and Drug Administration safety review.
once monthly as a single intravenous or subcutaneous injection to maintain target haemoglobin levels for patients currently being treated with an ESA (epoetin alfa, epoetin beta and darbepoetin alfa) who are converted to treatment with MIRCERA.
Trials have demonstrated that injecting epoetin alfa, a form of erythropoietin, improves brain function and quality of life in these people.
The European Agency for the Evaluation of Medicinal Products has already developed draft guidelines for generic versions of insulin, human growth factor, epoetin and colony stimulating factors (CSFs).